A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 (rAAV2tYF-PR1.7-hCNGB3) in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene

Trial Profile

A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 (rAAV2tYF-PR1.7-hCNGB3) in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Sep 2018

At a glance

  • Drugs A002-MeiraGTx (Primary)
  • Indications Colour vision defects
  • Focus Adverse reactions; First in man
  • Sponsors Applied Genetic Technologies Corporation
  • Most Recent Events

    • 10 Sep 2018 According to an Applied Genetic Technologies Corporation media release, eight patients has been enrolled across three dosing groups in this study.
    • 23 Jul 2018 According to an Applied Genetic Technologies Corporation media release, seven patients has been enrolled in this study.
    • 08 May 2018 According to an Applied Genetic Technologies Corporation media release, the company has enrolled one patient in lower dose group and expects to complete the dose escalation portion of this trial in the first quarter of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top